Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-06-14
2005-06-14
Webman, Edward J. (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S422000, C514S578000, C514S443000, C514S448000
Reexamination Certificate
active
06906086
ABSTRACT:
The current invention provides methods and pharmaceutical formulations that are useful for inhibiting the loss of bone. These methods and formulations can be used without the associated adverse effects of estrogen therapy, and thus serve as an effective and acceptable treatment for osteoporosis.
REFERENCES:
patent: 4133814 (1979-01-01), Jones et al.
patent: 4185108 (1980-01-01), Samour et al.
patent: 4380635 (1983-04-01), Peters
patent: 4418068 (1983-11-01), Jones
patent: 4729999 (1988-03-01), Young
patent: 4894373 (1990-01-01), Young
patent: 4970237 (1990-11-01), Jensen et al.
patent: 5011853 (1991-04-01), Olney
patent: 5075321 (1991-12-01), Schreiber
patent: 5118667 (1992-06-01), Adams
patent: 5208031 (1993-05-01), Kelly
patent: 5393763 (1995-02-01), Black et al.
patent: 5395842 (1995-03-01), Labrie et al.
patent: 5441947 (1995-08-01), Dodge et al.
patent: 5445941 (1995-08-01), Yang
patent: 5457116 (1995-10-01), Black et al.
patent: 5457117 (1995-10-01), Black et al.
patent: 5461065 (1995-10-01), Black et al.
patent: 5462949 (1995-10-01), Jones et al.
patent: 5464845 (1995-11-01), Black et al.
patent: 5468773 (1995-11-01), Dodge et al.
patent: 5472962 (1995-12-01), Koizumi et al.
patent: 5478847 (1995-12-01), Draper
patent: 5482949 (1996-01-01), Black et al.
patent: 5510370 (1996-04-01), Hock
patent: 5534527 (1996-07-01), Black et al.
patent: 5567713 (1996-10-01), Cullinan et al.
patent: 5591753 (1997-01-01), Black et al.
patent: 5624940 (1997-04-01), Bryant et al.
patent: 5629425 (1997-05-01), LaBell et al.
patent: 5641790 (1997-06-01), Draper
patent: 5646137 (1997-07-01), Black et al.
patent: 5731327 (1998-03-01), Luke
patent: 5747510 (1998-05-01), Draper
patent: 5811120 (1998-09-01), Gibson et al.
patent: 5972383 (1999-10-01), Gibson et al.
patent: 6087378 (2000-07-01), Cullinan et al.
patent: 6096781 (2000-08-01), Cullinan
patent: 6156786 (2000-12-01), Cullinan
patent: 6395769 (2002-05-01), Cullinan
patent: 6458811 (2002-10-01), Arbuthnot et al.
patent: 6713494 (2004-03-01), Cuff et al.
patent: 0062505 (1982-10-01), None
patent: 0068563 (1983-01-01), None
patent: 0605193 (1994-07-01), None
patent: 2097788 (1982-11-01), None
patent: 304924 (1992-12-01), None
patent: WO 93/10113 (1993-05-01), None
patent: WO98/10113 (1993-05-01), None
patent: WO 93/10741 (1993-06-01), None
Banks PK, Meyer K, Brodie AM H. Regulation of Ovarian Steroid Biosynthesis by Estrogen During Proestrus in the Rat. Endocrinology 1991;129(3):1295-1304.
Black LJ, Jones CD, Falcone JF. Antagonism of Estrogen Action with a New Benzothiophene Derived Antiestrogen. Life Sciences 1983;32:1031-1036.
Buzdar AU, Marcus C, Holmes F, Hug V, Hortobagyi G. Phase II Evaluation of LY156758 in Metastatic Breast Cancer, Oncology 1988;45(5):344-345.
Chou Y, Iguchi T, Bern H. Effects of Antiestrogens on Adult and Neonatal Mouse Reproductive Organs. Reprod Toxicol 1992;6(5):439-46.
Clemens JA, Bennett DR, Black LJ, Jones CD. Effects of a New Antiestrogen, Keoxifene (LY156758), on Growth of Carcinogen-Induced Mammary Tumors and on LH and Prolactin Levels. Life Sci 1983;32(25):2869-2875.
Cypriani B, Tabacik C, Descomps B, Crastes DP A. Role of Estrogen Receptors and Antiestrogen Binding Sites in an Early Effect of Antiestrogens, The Inhibition of Cholesterol Biosynthesis. J. Steroid Biochem 1988;31(5):763-771.
Cypriani B, Tabacik C, Descomps B. Effect on Estradiol and Antiestrogens on Cholesterol Biosynthesis in Hormone-Dependent and Independent Breast Cancer Cell Lines. Biochim. Biophys. Acta, ser Mol. Cell Res 1988:972(2):167-178.
Daniel CW, Silberstein GB, Strickland P. Direct action of 17beta-estradiol on mouse mammary ducts analyzed by sustained release implants and steroid autoradiography. Cancer Res 1987;47(22):6052-57.
De Launoit Y, Veilleux R, Dufour M, Simard J, Labrie F. Characteristics of the biphasic action of androgens and of the potent antiproliferative effects of the new pure antiestrogen EM-139 on cell cycle kinetic parameters in LNCaP human prostatic cancer cells. Cancer Res 1991;51(19):5165-5170.
Gierthy JF, Lincoln DW II, Roth KE, Bowser SS, Bennett JA, Bradley L and Dickerman HW. Estrogen-stimulation of postconfluent cell accumulation and foci formation of human MCF-7 breast cancer cells. J. Cell. Biochem 1991;45(2):177-187.
Gottardis MM, Jordan VC. Antitumor actions and keoxifene and tamoxifen in the n-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res 1987; 47(15):4020-4024.
Gottardis MM, Ricchio ME, Satyaswaroop PG, Jordan VC. Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCa101) in athymic mice. Cancer Res 1990;50(11):3189-3192.
Gray JM, Ziemian L. Antiestrogen binding sites in brain and pituitary of ovariectomized rats. Brain Res 1992;578(1-2):55-60.
Hubert J-F, Vincent A, Labrie F. Estrogenic activity of phenol red in rat anterior pituitary cell in culture. Biochem. Biophys. Res. Commun 1986;141(3):885-891.
Jordan VC, Gottardis MM. Tamoxifen-stimulated growth of human endometrial carcinoma. New York Acad. Sci 1991;622:439-446.
Jordan VC, Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens:problems and potential for future clinical applications. Breast cancer res. Treat 1983;3(Suppl):73-86.
Katz, J, Finlay, TH, Banerjee S, Levitz M. An Estrogen-Dependent Esterase Activity in MCF-7 Cells. J. Steroid Biochem. 1987;vol. 26, No. 6:687-692.
Kessel B, Hsueh AJW. Keoxifene (LY 156758) inhibits follicle-stimulating hormone induced differentiation of cultured rat granulosa cells. Life Sci 1987;40(11):1089-1097.
Kleinberg DL, Todd J, Babitsky G. Inhibition by estradiol of the lactogenic effect of prolactin in primate mammary tissue: reversal by antiestrogens LY 156758 and tamoxifen. Proc. Natl Acad. Sci. U.S.A. 1983;80:4144-4148.
Knecht M, Brodie AM H., Catt KJ. Aromatase inhibitors prevent granulosa cell differentiation: an obligatory role for estrogens in luteinizing hormone receptor expression. Endocrinology 1985;117(3):1156-1161.
Knecht M, Tsai-Morris CH, Catt KJ. Estrogen Dependence of Luteinizing Hormone Receptor Expression in Cultured Rat Granulosa Cells. Inhibition of Granulosa Cell Development by the Antiestrogens Tamoxifen and Keoxifene. Endocrinology 1985;16:1771-1777.
Labrie, F, Poulin R, Simard J, Zhao HF, Labrie C, Dauvois S et al. Interactions between estrogens, androgens, progestine, and glucocorticoids in ZR-75-1 human breast cancer cells. Ann. New York Acad. Sci 1990;595:130-148.
Labrie F, Simard J, Poulin R, Hatton A-C, Labrie C, Dauvois S et al. Potent antagonism between estrogens and androgens on GCDFP-15 expression and cell growth in the ZR-75-1 human breast cancer cells. Ann. New York Acad. Sci 1990;586:174-187.
Liehr JG, Folse DS, Roy D. Lack of effectiveness of antiestrogens RU 39,411 or keoxifen in the prevention of estrogen-induced tumors in Syrian hamsters. Cancer Lett 1992;64(1):23-29.
Lindstrom TD, Whitaker NG, Whitaker GW. Disposition and metabolism of a new benzothiophene antiestrogen in rats, dogs and monkeys. Xenobiotica 1984;14(11):841-847.
Luthy IA, Begin D, Labrie F. Mediation by the androgen receptor of the stimulatory and antiandrogenic actions of 17β-estradiol on the growth of androgen-sensitive shionogi mammary carcinoma cells in culture. Endocrinology 1988;123(3):1418-1424.
Mariotti A, Durham J, Frederickson R, Miller R, Butcher F, Mawhinney M. Actions and Interactions of estradiol and retinoic acid in mouse anterior prostate gland. Biol. Reprod 1987;37(4):1023-1035.
Martinoli MG, Veilleux R, Pelletier G. Effects of triiodothyronine, dexamethasone and estradiol-17β on GH mRNA in rat pituitary cells in culture as revealed by in situ hybridization. Acta Endocrinol 1991;124(1):83-90.
McArdle CA, Schomerus E, Groner I, Poch A. Estradiol regulates gonadotropin-releasing hormone receptor number, growth and inositol phosphate production in αT3-1 cells. Mol. Cell. Endocrinol 1992;87(1-3):95-103.
Meisel RL, Dohanich GP, McEwen BS, Pfaff DW. Antagonism of sexual behavior in female rats by ventromedial hypothala
Eli Lilly and Company
Webman Edward J.
Woodard Emhardt Moriarty McNett & Henry LLP
LandOfFree
Methods for inhibiting bone loss does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for inhibiting bone loss, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for inhibiting bone loss will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3516296